ENLIVEN THERAPEUTICS INC (ELVN)
Health Care · Biotechnology · NASDAQ
Enliven Therapeutics is a precision oncology company developing next-generation small molecule inhibitors, led by its clinical-stage BCR-ABL program for chronic myeloid leukemia.
What ENLIVEN THERAPEUTICS INC does
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors for the treatment of patients with cancer. Its primary asset, ELVN-001, is a BCR-ABL inhibitor currently in clinical development for the treatment of chronic myeloid leukemia (CML). The company utilizes a precision medicine approach to address patient populations with significant unmet needs.
Themes: oncology, precision medicine, chronic myeloid leukemia, clinical-stage biotech
Fundamentals
- Price$59.82 as of 2026-08-21 close
- Market cap$4.4B as of 2026-08-21
- 1-year return+201.5% 2025-08-21 close $19.84 → 2026-08-21 close $59.82
- P/En/a earnings data not available
- ROE-18.6% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.46 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How ELVN compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ELVN is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
61.7 #141 of 1,704 scored · #35 of 240 in Health Care
Trend 79th: a strong uptrend, with buyers in control; setup 63rd: no fresh 20-day breakout up or down; weakest is catalysts 42nd: open-market insider buys in 90 days 5, analysts' average price target is unchanged from the prior reading.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How ENLIVEN THERAPEUTICS INC looks technically
ENLIVEN THERAPEUTICS INC (ELVN) is trading 68.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 146 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It made a new 20-day high about 14 trading days ago. It is 4.0% below its 52-week high (its highest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 68.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +68.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $52.82 | $52.82 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $35.43 | $35.43 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 56.69. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 3 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 146 trading days ago — a "golden cross", a bullish long-term signal | 146 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with buyers in control | 37.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 63.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($56.69 to $62.32) — its "stochastic" reading is 56 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 55.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $62.32 | $62.32 |
|---|---|---|
| From the 52-week high | it is 4.0% below its 52-week high (its highest price of the past year) | -4.0% |
| Above the 52-week low | it is 304.6% above its 52-week low (its lowest price of the past year) | +304.6% |
| Below the 52-week high | it is 4.0% below its highest point of the past year | 4.0% |
| Since a 20-day breakout | it made a new 20-day high about 14 trading days ago | 14 sessions |
| Since a 55-day breakout | it made a new 55-day high about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $250.84 (set on 2020-06-09) | $250.84 |
| Given back of the 52-week move | over the past year its closes ranged ($15.14 to $61.11), and it has given back only a small part of its rise from last year’s low — 3% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $31.23 to $32.70. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 2.8% |
| From the all-time high | it is 76.2% below its all-time high | -76.2% |
| Nearest price level | it is trading 49.8% above a support level at $30.00 — a price it turned at four times since 2024-10-18, most recently on 2026-02-06. Since 2024-08-21 it has 15 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -49.8% |
| All-time low | its lowest closing price on record is $3.90 (set on 2022-04-13) | $3.90 |
| Above the all-time low | it is 1435.4% above its all-time low | +1,435% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 34th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.46 between its high and its low — about 4.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.46 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $52.69 and $63.17 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $52.69 – $57.93 – $63.17 |
| Typical daily range (% of price) | its price moves about 4.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.1% |
| Stretch from the 200-day average | it is trading 9.9 daily ranges above its 200-day average price (68.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 9.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.65× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
4
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 33.8% above the previous close 49 sessions ago and has not traded back through the level it left behind at 33.63 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +33.8% |
| Gap filled | a 2.2% gap down opened on 2026-07-17 has been "filled" 25 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 25 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 7.8 percentage points (the stock gained 10.1% while the market gained 2.3%) | +7.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 38.5 percentage points (the stock gained 41.6% while the market gained 3.1%) | +38.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 118.8 percentage points (the stock gained 129.9% while the market gained 11.1%) | +118.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 181.0 percentage points (the stock gained 201.5% while the market gained 20.5%) | +181.0% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 26% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.3% of the share price. | +26.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 49% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $40.03 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +49.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $59.38 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +0.8% |
Price levels it has turned at before
ELVN last closed at $59.82 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $30.00 | Support | 49.8% below the last close | turned there four times · 2024-10-18 to 2026-02-06 |
| $28.66 | Support | 52.1% below the last close | turned there twice · 2024-10-09 to 2026-01-22 |
| $26.80 | Support | 55.2% below the last close | turned there twice · 2024-11-01 to 2026-03-18 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $56.69.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $85.56 and $103.40 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a strong, established uptrend (ADX) · beating the market · Stretched far above its 200-day average (6+ daily ranges) · Trading above the Ichimoku cloud · Elliott wave 3 candidates | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$72.22 range $62.00 – $82.00; median $70.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ELVN
- Consensus EPS estimate-$0.4767 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on successful clinical trial results for product candidates to obtain regulatory approval.","Significant competition from established pharmaceutical companies with greater resources.","Dependence on third parties for the clinical trial execution and drug manufacturing processes."]
What changed in the latest 10-Q
AI-assisted comparison of ELVN's 10-Q filed 2026-05-07 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Added statement in Overview: 'are no longer pursuing its development' regarding ELVN-002 program (2026 filing)
- Added bullet point: 'make changes to our clinical development plan for ELVN-001' in expenses discussion (2026 filing)
- Added phrase 'medical and' before 'distribution infrastructure' in infrastructure bullet point (2026 filing)
- Changed language from 'which we expect to increase' to 'which may increase' regarding manufacturing cost expectations (2026 filing)
- Removed:
- Removed team expertise section describing 'seasoned drug hunters' and listing FDA-approved products (Koselugo, Mektovi, Tukysa, Retevmo) from Overview (2025 filing had this content)
- Removed reference to 'HER2' program in description of Former Enliven's research focus; changed from 'BCR-ABL and human epidermal growth factor receptor 2 (HER2) programs' to 'BCR-ABL program' (2026 filing)
- Removed phrase 'and we do not intend to pursue its development beyond 2025' regarding ELVN-002; replaced with 'are no longer pursuing its development' (2026 filing)
- Removed reference to 'ELVN-001 and ELVN-002 programs' in table caption; changed to 'clinical programs' (2026 filing)
- Removed 'several' descriptor; changed 'pursuing several additional research stage opportunities' to 'pursuing multiple additional research-stage opportunities' (2026 filing)
- Removed detailed definition: 'Clinically validated targets refers to biological targets that have demonstrated statistical significance on efficacy endpoints in published third-party clinical trials' (2025 filing had this)
- Removed 'precision oncology approach'; changed to 'precision medicine approach' (2026 filing)
- Removed reference to 'where we sold' in Public Offering description (2026 filing)
- Reworded:
- Changed from 'precision oncology approach' to 'precision medicine approach' in Overview (2026 filing)
- Changed from 'in clinically validated' to 'into clinically validated' in discovery process description (2026 filing)
- Changed from 'develop drugs with an increased probability' to 'develop drugs that address unmet needs with an increased probability' (2026 filing)
- Changed from 'do not intend to pursue its development beyond 2025' to 'are no longer pursuing its development' regarding ELVN-002 (2026 filing)
- Changed from 'several additional research stage opportunities' to 'multiple additional research-stage opportunities' (2026 filing)
- Changed reference date from 'September 30, 2025' to 'March 31, 2026' throughout (2026 filing)
- Changed cash position from '$477.6 million' to '$452.4 million' as of reporting date (2026 filing)
- Changed accumulated deficit from '$317.5 million' to '$370.8 million' (2026 filing)
- Changed net loss reference from '$89.0 million and $71.6 million for years ended December 31, 2024 and 2023' to '$103.7 million and $89.0 million for years ended December 31, 2025 and 2024' plus '$23.6 million for three months ended March 31, 2026' (2026 filing)
- Changed from 'nine months ended September 30, 2025' of '$74.0 million' to 'three months ended March 31, 2026' of '$23.6 million' (2026 filing)
- Changed from 'sales, marketing and distribution' to 'sales, marketing, medical and distribution' in infrastructure bullet (2026 filing)
- Changed from 'which we expect to increase' to 'which may increase' regarding manufacturing costs in Europe (2026 filing)
- Notes:
- Text comparison limited by truncation at end of both filings; complete bullet point lists and final paragraphs not fully visible
- Team expertise section completely removed from 2026 filing but was present in 2025 filing
- Company appears to have made strategic decision to discontinue HER2 program and shift ELVN-002 approach between the two filing dates
Risk Factors
- Added:
- Added language in newer filing (2026-05-07): 'the ability of our product candidates to compete with such competing therapies' in the competitive position bullet point
- Removed:
- Removed from older filing (2025-11-12): reference to 'ELVN-002 from our HER2 (as defined below) program' in the clinical trials bullet point
- Removed from older filing (2025-11-12): 'our expectations regarding the exploration of strategic alternatives for ELVN-002' as a separate forward-looking statement bullet
- Removed from older filing (2025-11-12): reference to 'ELVN-002 from our HER2 program' in the intellectual property bullet point
- Removed from older filing (2025-11-12): 'or other arrangements' phrase - now reads 'drug supply, or other arrangements' in newer filing
- Reworded:
- Newer filing (2026-05-07) changed 'our expectations regarding the government shutdown' to 'our expectations regarding conditions and risks related to government shutdowns' (plural form with added context)
- Older filing (2025-11-12) referred to 'the Company's development of a companion diagnostic' while newer filing (2026-05-07) changed to 'our development of a companion diagnostic' (pronoun consistency)
- Older filing (2025-11-12) stated 'our ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements' while newer filing (2026-05-07) added 'drug supply,' making it 'drug supply, or other arrangements'
- Older filing (2025-11-12) had 'the success of competing therapies that are or may become available' while newer filing (2026-05-07) added 'and the ability of our product candidates to compete with such competing therapies'
- Notes:
- Page numbers in table of contents changed between filings (Risk Factors moved from page 37 to page 35), but this reflects document length changes rather than substantive content changes
- Text appears to be truncated at the end of both excerpts ('In addition, statements such as'), limiting full assessment of any additional changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 28 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($10M) — 1 selling insider
- Last 90 days0 buys · 28 sells ($63M) — 5 selling insiders
- Last 180 days0 buys · 39 sells ($67M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-04. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ELVN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding ELVN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 13,476,574
- Reported value $528,281,700
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ELVN had 8,151,554 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ELVN had 11.1% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.44 days to cover at the same settlement.
- Reported short interest (shares) 8,151,554
- Short interest (% of shares outstanding) 11.1%
- Prior settlement (shares) 8,651,596
- Reported change -5.78%
- Days to cover (reported) 11.44
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
- Takeda Pharmaceutical (TAK)
- Pfizer (PFE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ELVN vs…
ENLIVEN THERAPEUTICS INC is found in…
Frequently asked questions
What does ENLIVEN THERAPEUTICS INC (ELVN) do?
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors for the treatment of patients with cancer. Its primary asset, ELVN-001, is a BCR-ABL inhibitor currently in clinical development for the treatment of chronic myeloid leukemia (CML). The company utilizes a precision medicine approach to address patient populations with significant unmet needs.
What sector is ENLIVEN THERAPEUTICS INC (ELVN) in?
ENLIVEN THERAPEUTICS INC (ELVN) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are ENLIVEN THERAPEUTICS INC's (ELVN) competitors?
Notable peers of ENLIVEN THERAPEUTICS INC (ELVN) include Novartis, Bristol Myers Squibb, Takeda Pharmaceutical and Pfizer. This peer set is informational only — not financial advice.
Is ENLIVEN THERAPEUTICS INC (ELVN) overbought or oversold right now?
ENLIVEN THERAPEUTICS INC (ELVN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ELVN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.